The serine/threonine kinase AKT is a key component of the PI3K/AKT/mTOR signaling
pathway as it exerts a pivotal role in cell growth, proliferation, survival, and metabolism …

Advances in medical sciences and evidence-based medicine have led to momentous
changes in classification and management of thyroid neoplasms. Much progress has been …

Background Combined therapy with dabrafenib plus trametinib was approved in several
countries for treatment of BRAF V600E-mutant anaplastic thyroid cancer (ATC) based on an …

Most malignant thyroid tumours are initially treated with surgery or a combination of surgery
and radioactive iodine (RAI) therapy. However, in patients with metastatic disease, many …

The knowledge on thyroid cancer biology has grown over the past decade. Thus, diagnostic
and therapeutic strategies to manage thyroid cancer are rapidly evolving. With new insights …

Differentiated thyroid cancers (DTC) are commonly and successfully treated with total
thyroidectomy plus/minus radioiodine therapy (RAI). Medullary thyroid cancer (MTC) is only …

This manuscript investigates cabozantinib, vandetanib, pralsetinib, and selpercatinib, four
tyrosine kinase inhibitors (TKIs), which are used to treat advanced and/or metastatic …

Thyroid cancers (TCs) are the most common tumors of the endocrine system and a constant
rise in the number of TC cases has been observed for the past few decades. TCs are one of …

Abstract BRAF V600E mutation is one of the most therapeutic targets in thyroid cancers.
However, its specific inhibitors have shown little clinical benefit because they can reactivate …

Immune system plays a key role in cancer prevention as well as in its initiation and
progression. During multistep development of tumors, cells must acquire the capability to …